Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | FAAH | O00519 | 2/20 | 0.60 |
| ▸ | CNR2 | P34972 | 2/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15557719 | 1.00 | CNR1 (0.75) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL17292254 | 1.00 | CNR1 (0.75) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL2493620 | 0.90 | CNR1 (0.79) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL12318762 | 0.90 | CNR1 (0.79) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14739566 | 0.90 | CNR1 (0.66) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14739564 | 0.90 | CNR1 (0.66) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL15253154 | 0.88 | CNR1 (0.75) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL15253153 | 0.88 | CNR1 (0.75) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL14958854 | 0.87 | CNR1 (0.82) | CNR1ALDH1A1FAAHCNR2TRPM8 | |
| SCHEMBL8052707 | 0.86 | CNR1 (1.00) | CNR1ALDH1A1FAAHCNR2TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | Catabasis Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | CNR1 2881/4885ALDH1A1 3440/4885FAAH 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.